Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study

BackgroundPD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zheng Yan, Jialin Ma, Shuna Yao, Zhihua Yao, Haiying Wang, Junfeng Chu, Shuang Zhao, Yanyan Liu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	PD-1 Hodgkin lymphoma immunotherapy apatinib camrelizumab anti-angiogenic agent Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/b26eb31a0d1f4e158142db1d711bca9a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b26eb31a0d1f4e158142db1d711bca9a
record_format	dspace
spelling	oai:doaj.org-article:b26eb31a0d1f4e158142db1d711bca9a2021-12-01T07:29:31ZAnti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study1664-322410.3389/fimmu.2021.727464https://doaj.org/article/b26eb31a0d1f4e158142db1d711bca9a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.727464/fullhttps://doaj.org/toc/1664-3224BackgroundPD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When immunotherapy failed, alternative treatment options are limited. In the past few years, we have used the anti-angiogenic agent apatinib and PD-1 inhibitor camrelizumab to treat cHL patients who failed prior immunotherapy. In this study, we analyzed the data of these patients.Patients and MethodsPatients with r/r cHL who had failed immunotherapy and subsequently received apatinib-camrelizumab (AC) combination therapy were included in this study. Patient data were collected from medical records and follow-up system. The efficacy and safety of AC therapy were analyzed.ResultsSeven patients who failed immunotherapy were identified in our database, of which five patients acquired immunotherapy resistance and two patients experienced severe side effects. They received a combination of camrelizumab (200 mg every four weeks) and apatinib (425 mg or 250 mg per day). As of the cut-off date, these patients had received a median of 4 cycles (range, 2 - 31) of treatment. Two (2/7) patients achieved complete response, four (4/7) partial response, and one (1/7) stable disease. The median progression-free survival was 10.0 months (range, 2.0 – 27.8). Low-dose apatinib (250 mg) plus camrelizumab was well tolerated and had no unexpected side effects. Besides, no reactive cutaneous capillary endothelial proliferation was observed in AC-treated patients.ConclusionsLow dose apatinib plus camrelizumab might be a promising treatment option for r/r cHL patients who have failed immunotherapy. This combination treatment is worthy of further investigation in more patients including solid cancer patients who have failed immunotherapy.Zheng YanJialin MaShuna YaoZhihua YaoHaiying WangJunfeng ChuShuang ZhaoYanyan LiuFrontiers Media S.A.articlePD-1Hodgkin lymphomaimmunotherapyapatinibcamrelizumabanti-angiogenic agentImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PD-1 Hodgkin lymphoma immunotherapy apatinib camrelizumab anti-angiogenic agent Immunologic diseases. Allergy RC581-607
spellingShingle	PD-1 Hodgkin lymphoma immunotherapy apatinib camrelizumab anti-angiogenic agent Immunologic diseases. Allergy RC581-607 Zheng Yan Jialin Ma Shuna Yao Zhihua Yao Haiying Wang Junfeng Chu Shuang Zhao Yanyan Liu Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
description	BackgroundPD-1/PD-L1 inhibitor immunotherapy has showed impressive activity in various cancers, especially relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). However, acquired resistance is inevitable for most patients. Sometimes severe side effects also lead to treatment termination. When immunotherapy failed, alternative treatment options are limited. In the past few years, we have used the anti-angiogenic agent apatinib and PD-1 inhibitor camrelizumab to treat cHL patients who failed prior immunotherapy. In this study, we analyzed the data of these patients.Patients and MethodsPatients with r/r cHL who had failed immunotherapy and subsequently received apatinib-camrelizumab (AC) combination therapy were included in this study. Patient data were collected from medical records and follow-up system. The efficacy and safety of AC therapy were analyzed.ResultsSeven patients who failed immunotherapy were identified in our database, of which five patients acquired immunotherapy resistance and two patients experienced severe side effects. They received a combination of camrelizumab (200 mg every four weeks) and apatinib (425 mg or 250 mg per day). As of the cut-off date, these patients had received a median of 4 cycles (range, 2 - 31) of treatment. Two (2/7) patients achieved complete response, four (4/7) partial response, and one (1/7) stable disease. The median progression-free survival was 10.0 months (range, 2.0 – 27.8). Low-dose apatinib (250 mg) plus camrelizumab was well tolerated and had no unexpected side effects. Besides, no reactive cutaneous capillary endothelial proliferation was observed in AC-treated patients.ConclusionsLow dose apatinib plus camrelizumab might be a promising treatment option for r/r cHL patients who have failed immunotherapy. This combination treatment is worthy of further investigation in more patients including solid cancer patients who have failed immunotherapy.
format	article
author	Zheng Yan Jialin Ma Shuna Yao Zhihua Yao Haiying Wang Junfeng Chu Shuang Zhao Yanyan Liu
author_facet	Zheng Yan Jialin Ma Shuna Yao Zhihua Yao Haiying Wang Junfeng Chu Shuang Zhao Yanyan Liu
author_sort	Zheng Yan
title	Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_short	Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_full	Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_fullStr	Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_full_unstemmed	Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
title_sort	anti-angiogenic agent combined with anti-pd-1 immunotherapy showed activity in patients with classical hodgkin lymphoma who have failed immunotherapy: a retrospective case report study
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/b26eb31a0d1f4e158142db1d711bca9a
work_keys_str_mv	AT zhengyan antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT jialinma antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT shunayao antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT zhihuayao antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT haiyingwang antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT junfengchu antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT shuangzhao antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy AT yanyanliu antiangiogenicagentcombinedwithantipd1immunotherapyshowedactivityinpatientswithclassicalhodgkinlymphomawhohavefailedimmunotherapyaretrospectivecasereportstudy
_version_	1718405434899955712

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study

Ejemplares similares